Statins: A Panacea to Reduce Mortality in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma?
- 27 November 2021
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Liver Transplantation
- Vol. 28 (3), 357-358
- https://doi.org/10.1002/lt.26381
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Anticancer Effect of Statins in Patients Undergoing Liver Transplantation for Hepatocellular CarcinomaLiver Transplantation, 2021
- Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosisHepatology International, 2021
- Statin use and the prognosis of patients with hepatocellular carcinoma: a meta-analysisBioscience Reports, 2020
- Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinomaJournal of Hepatology, 2019
- Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor MicroenvironmentCell Metabolism, 2019
- Statins for Prevention of Cardiovascular Disease in AdultsJAMA, 2016
- The interplay between cell signalling and the mevalonate pathway in cancerNature Reviews Cancer, 2016
- Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference reportThe Lancet Oncology, 2012
- Statin Therapy Ameliorates Renal Allograft FunctionTransplantation Proceedings, 2009